


PHARMACEUTICAL 2021

Lipocine Inc. Rank 267 of 402









PHARMACEUTICAL 2021

Lipocine Inc. Rank 267 of 402



The relative strengths and weaknesses of Lipocine Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lipocine Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Lipocine Inc. is the variable Net Income, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 31%, being 17% points below the market average of 47%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 25,329 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 6,584 |
| Liabilities, Non-Current | 2,257 |
| Other Assets | 24 |
| Other Compr. Net Income | 0.038 |
| Other Expenses | 0.20 |
| Other Liabilities | 1,170 |
| Other Net Income | -2,968 |
| Other Revenues | 0 |
| Property and Equipment | 0 |
| Research and Development | 9,748 |
| Selling, General and Administrative Expense | 8,248 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 25,353 |
| Liabilities | 10,011 |
| Expenses | 17,996 |
| Revenues | 0 |
| Stockholders Equity | 15,342 |
| Net Income | -20,965 |
| Comprehensive Net Income | -20,965 |
| Economic Capital Ratio | 31% |

